Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, P. R. China.
Cancer Commun (Lond). 2021 Aug;41(8):747-795. doi: 10.1002/cac2.12193. Epub 2021 Jul 1.
There exist differences in the epidemiological characteristics, clinicopathological features, tumor biological characteristics, treatment patterns, and drug selections between gastric cancer patients from the Eastern and Western countries. The Chinese Society of Clinical Oncology (CSCO) has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it annually. Taking into account regional differences, giving full consideration to the accessibility of diagnosis and treatment resources, these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in China. The 2021 CSCO Clinical Practice Guidelines for Gastric Cancer covers the diagnosis, treatment, follow-up, and screening of gastric cancer. Based on the 2020 version of the CSCO Chinese Gastric Cancer guidelines, this updated guideline integrates the results of major clinical studies from China and overseas for the past year, focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant recommendations. For the comprehensive treatment of non-metastatic gastric cancer, attentions were paid to neoadjuvant treatment. The value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been updated. For the comprehensive treatment of metastatic gastric cancer, recommendations for immunotherapy were included, and immune checkpoint inhibitors from third-line to the first-line of treatment for different patient groups with detailed notes are provided.
东西方国家的胃癌患者在流行病学特征、临床病理特征、肿瘤生物学特征、治疗模式和药物选择方面存在差异。中国临床肿瘤学会（CSCO）自 2016 年以来组织了一个专门从事胃癌各亚专科的高级专家小组，编写了胃癌的诊断和治疗临床指南，并每年更新。考虑到地区差异，充分考虑诊断和治疗资源的可及性，这些专家对相关证据进行了专家共识判断，并对胃癌的临床诊断和治疗进行了各种级别的推荐，以反映中国癌症治疗的价值和满足卫生经济指标。2021 年 CSCO 胃癌临床实践指南涵盖了胃癌的诊断、治疗、随访和筛查。该指南在 2020 年版 CSCO 中国胃癌指南的基础上，整合了过去一年来自中国和海外的主要临床研究结果，重点纳入了中国人群的研究数据，以提供更具个性化和更具临床相关性的建议。对于非转移性胃癌的综合治疗，关注新辅助治疗。围手术期化疗的价值逐渐变得更加清晰，其推荐级别也得到了更新。对于转移性胃癌的综合治疗，包括了免疫治疗的建议，并为不同患者群体提供了详细注释的从三线到一线治疗的免疫检查点抑制剂的建议。
